to take place May 30-June 3, in Chicago, Illinois. The oral presentation will highlight topline Phase 2 (Actuate-1801 Part 3B) data of elraglusib in combination with GnP in first-line mPDAC and ...

IMUNON initiates Phase 3 OVATION 3 study for IMNN-001 in advanced ovarian cancer; Phase 2 data accepted for ASCO presentation. IMUNON, Inc. has initiated the first trial site for its Phase 3 ...

Phase 3 of the Ireland/Ironwood intersection project begins. During this phase, work will focus on the center lanes of Ironwood Drive. That means left turns will be prohibited from all directions ...

American consumers were snapping up Toyota Motor’s hybrids ... It cited headwinds from a stronger yen and predicted a $1.3 billion hit from President Trump’s tariffs in April and May alone.

She regularly appears on CBS News 24/7 to discuss her reporting. Ford Motor on Wednesday said it is raising prices on three models produced in Mexico, pointing to higher U.S. tariffs on imported ...

Tamil Nadu Deputy Chief Minister Udhayanidhi Stalin on Thursday (May 1, 2025) inaugurated the work on the third phase of the Chennai Peripheral Ring Road project (CPRR), undertaken by the State ...

On Wednesday, RTÉ confirmed it wrote down €3.6m on a partly failed ... Yesterday, Media Minister Patrick O’Donovan said he first learnt of the write-down after it emerged earlier this year ...

RTÉ has confirmed it wrote down €3.6 million on a partly failed IT project ... The details of the write-down were revealed by The Currency. In a statement to the Irish Independent, a RTÉ ...

The 2025 American Society of Clinical Oncology (ASCO), annual meeting will take place in Chicago from May 30 to June 3, 2025. TG4050— Rapid oral presentation details: Title: “Randomized Phase I trial ...

For those who don't need the fastest possible next best thing, there's the new Polestar 3 Single Motor "Long Range." This is exactly what Polestar has done with the new single-motor variant of the ...

Dr. DeWeese has no relationship with Candel, other than serving as the national principal investigator for Candel’s phase 3 clinical trial of CAN-2409 in patients with intermediate-to-high risk ...